Abstract: Dry extract from kava-kava drug having a total content of kava lactones of at least 50% by weight and a flavokawin content of at the most 0.3% by weight. The extract is distinguished by good water solubility and high bioavailability after oral administration. To increase the kava lactone content in the extract and decrease the flavokawin content, a process is proposed in which the raw extract is brought into solution and the content of flavokawins diminished by cold precipitation or by solvent distribution, whereafter the solution is concentrated to dryness. Drugs are made using the dry extract.